May 18, 2026 | Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA

Regeneron's fianlimab misses PFS endpoint in melanoma, erasing ~$8B in market cap. Supreme Court rejects IRA pricing challenges from six pharma companies. FDA approves AstraZeneca's first-in-class Baxfendy for hypertension. Merck's sac-TMT scores Phase 3 dual-endpoint win.Visit us at www.thepharmacloseput.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, fianlimab, LAG-3, melanoma, REGN, Keytruda, pembrolizumab, Merck, sac-TMT, sacituzumab tirumotecan, endometrial cancer, Kelun-Biotech, AstraZeneca, Baxfendy, baxdrostat, hypertension, Supreme Court, IRA, drug pricing, Medicare, Amgen, Tavneos, avacopan, CDER, Sara Høeg, Bristol Myers Squibb, Enhertu, Parabilis Medicines, Novo Nordisk, Novartis, Bristol-Myers, BMS